The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.
Cancer immunoediting from immune surveillance to immune escape
Open accessAbstract
Summary: Cancer immune surveillance is considered to be an important host protection process to inhibit carcinogenesis and to maintain cellular homeostasis. In the interaction of host and tumour cells, three essential phases have been proposed: elimination, equilibrium and escape, which are designated the ‘three E’s'. Several immune effector cells and secreted cytokines play a critical role in pursuing each process. Nascent transformed cells can initially be eliminated by an innate immune response such as by natural killer cells. During tumour progression, even though an adaptive immune response can be provoked by antigen‐specific T cells, immune selection produces tumour cell variants that lose major histocompatibility complex class I and II antigens and decreases amounts of tumour antigens in the equilibrium phase. Furthermore, tumour‐derived soluble factors facilitate the escape from immune attack, allowing progression and metastasis. In this review, the central roles of effector cells and cytokines in tumour immunity, and the escape mechanisms of tumour cells during tumour progression are discussed.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Nuclear factor-κB in cancer development and progression
Karin, M. (2006) · Nature · doi:10.1038/nature04870 · Cited by 3,519
Demonstration of an interferon γ-dependent tumor surveillance system in immunocompetent mice
Kaplan, D. H., Shankaran, V., Dighe, A. S., Stockert, E., Aguet, M., Old, L. J., & Schreiber, R. D. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.13.7556 · Cited by 1,465
Dighe, A. S., Richards, E., Old, L. J., & Schreiber, R. D. (1994) · Immunity · doi:10.1016/1074-7613(94)90087-6 · Cited by 663
The p53 response to DNA damage
Meek, D. W. (2004) · DNA Repair · doi:10.1016/j.dnarep.2004.03.027 · Cited by 329
Malignancy in Renal Transplantation
Morath, C., Mueller, M., Goldschmidt, H., Schwenger, V., Opelz, G., & Zeier, M. (2004) · Journal of the American Society of Nephrology · doi:10.1097/01.asn.0000126194.77004.9b · Cited by 229
Cited by
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation
Dhatchinamoorthy, K., Colbert, J. D., & Rock, K. L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.636568 · Cited by 1,077
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Monteran, L., & Erez, N. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.01835 · Cited by 675
Baruch, K., Rosenzweig, N., Kertser, A., Deczkowska, A., Sharif, A. M., Spinrad, A., Tsitsou-Kampeli, A., Sarel, A., Cahalon, L., & Schwartz, M. (2015) · Nature Communications · doi:10.1038/ncomms8967 · Cited by 491
Pembrolizumab Cutaneous Adverse Events and Their Association With Disease Progression
Sanlorenzo, M., Vujic, I., Daud, A., Algazi, A., Gubens, M., Luna, S. A., Lin, K., Quaglino, P., Rappersberger, K., & Ortiz-Urda, S. (2015) · JAMA Dermatology · doi:10.1001/jamadermatol.2015.1916 · Cited by 449
Endocrine Side Effects Induced by Immune Checkpoint Inhibitors
Corsello, S. M., Barnabei, A., Marchetti, P., De Vecchis, L., Salvatori, R., & Torino, F. (2013) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2012-4075 · Cited by 403
Aging and cancer: The role of macrophages and neutrophils
Jackaman, C., Tomay, F., Duong, L., Abdol Razak, N. B., Pixley, F. J., Metharom, P., & Nelson, D. J. (2017) · Ageing Research Reviews · doi:10.1016/j.arr.2017.03.008 · Cited by 251
The tumour microenvironment and immune milieu of cholangiocarcinoma
Fabris, L., Perugorria, M. J., Mertens, J., Björkström, N. K., Cramer, T., Lleo, A., Solinas, A., Sänger, H., Lukacs‐Kornek, V., Moncsek, A., et al. (2019) · Liver International · doi:10.1111/liv.14098 · Cited by 187
Middlebrooks, C. D., Banday, A. R., Matsuda, K., Udquim, K.-I., Onabajo, O. O., Paquin, A., Figueroa, J. D., Zhu, B., Koutros, S., Kubo, M., et al. (2016) · Nature Genetics · doi:10.1038/ng.3670 · Cited by 185
Hepatic Stellate Cell-Macrophage Crosstalk in Liver Fibrosis and Carcinogenesis
Matsuda, M., & Seki, E. (2020) · Seminars in Liver Disease · doi:10.1055/s-0040-1708876 · Cited by 189
The Role of Tumor Microenvironment in Cancer Immunotherapy
Frankel, T., Lanfranca, M. P., & Zou, W. (2017) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-319-67577-0_4 · Cited by 173
Reciprocal cellular cross-talk within the tumor microenvironment promotes oncolytic virus activity
Ilkow, C. S., Marguerie, M., Batenchuk, C., Mayer, J., Ben Neriah, D., Cousineau, S., Falls, T., Jennings, V. A., Boileau, M., Bellamy, D., et al. (2015) · Nature Medicine · doi:10.1038/nm.3848 · Cited by 165
Sasidharan Nair, V., Toor, S. M., Ali, B. R., & Elkord, E. (2018) · Expert Opinion on Therapeutic Targets · doi:10.1080/14728222.2018.1471137 · Cited by 159
Zhang, N., Li, M., Sun, X., Jia, H., & Liu, W. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2018.01.007 · Cited by 136
Evolving immunosuppressive microenvironment during human cervical carcinogenesis
Kobayashi, A., Weinberg, V, Darragh, T., & Smith-McCune, K. (2008) · Mucosal Immunology · doi:10.1038/mi.2008.33 · Cited by 136
Berest, I., Arnold, C., Reyes-Palomares, A., Palla, G., Rasmussen, K. D., Giles, H., Bruch, P.-M., Huber, W., Dietrich, S., Helin, K., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.10.106 · Cited by 119
Immunotherapy in breast cancer: Current status and future directions
(2019) · Advances in Cancer Research · doi:10.1016/bs.acr.2019.03.006 · Cited by 109
Delivery Strategies for Immune Checkpoint Blockade
Chen, Q., Wang, C., Chen, G., Hu, Q., & Gu, Z. (2018) · Advanced Healthcare Materials · doi:10.1002/adhm.201800424 · Cited by 90
Foote, C. A., Soares, R. N., Ramirez‐Perez, F. I., Ghiarone, T., Aroor, A., Manrique‐Acevedo, C., Padilla, J., & Martinez‐Lemus, L. (2022) · Comprehensive Physiology · doi:10.1002/j.2040-4603.2022.tb00232.x · Cited by 89
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Leidinger, P., Backes, C., Dahmke, I. N., Galata, V., Huwer, H., Stehle, I., Bals, R., Keller, A., & Meese, E. (2014) · Oncotarget · doi:10.18632/oncotarget.2419 · Cited by 54
Data-Driven Mathematical Model of Osteosarcoma
Le, T., Su, S., Kirshtein, A., & Shahriyari, L. (2021) · Cancers · doi:10.3390/cancers13102367 · Cited by 39
Guo, X., Liu, Y., Kim, J. L., Kim, E. Y., Kim, E. Q., Jansen, A., Li, K., Chan, M., Keenan, B. T., Conejo-Garcia, J., et al. (2019) · PLOS ONE · doi:10.1371/journal.pone.0212930 · Cited by 23
Development and Validation of a Robust Immune-Related Prognostic Signature for Gastric Cancer
Huo, J., Wu, L., & Zang, Y. (2021) · Journal of Immunology Research · doi:10.1155/2021/5554342 · Cited by 16
Metadata
- Authors
- Kim, R., Emi, M., & Tanabe, K.
- Venue
- Immunology
- Publisher
- Wiley
- Published
- 2007-03-26
- Volume
- 121
- Issue
- 1
- Pages
- 1-14
- ISSN
- 0019-2805 (ISSN-L)
- 1365-2567
- OpenAlex
- W1996398553
- Cited by
- 1,074
- References
- 6
- FWCI
- 9.66
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
